ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Altimmune Inc (ALT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising prospects in its pipeline, the current technical indicators, recent price trends, and financial performance do not align with an immediate investment opportunity. The stock is better suited for investors willing to take on higher risk and wait for clearer signals of growth.
The technical indicators suggest a bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 28.295, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with the nearest support at 3.235 and resistance at 3.633.
Analysts have a positive outlook with multiple Buy ratings and high price targets (ranging from $7 to $25).
Insiders are buying, with a 333.56% increase in buying activity over the last month.
The company's lead asset, pemvidutide, shows promise in treating liver-related diseases and alcohol use disorder, with potential peak revenues of $600M-$1B.
The stock has been underperforming, with a -3.32% regular market change and bearish technical indicators.
Financials show a significant net loss of -$27.36M in Q4 2025, despite a revenue increase.
Competition in the biopharmaceutical sector is intensifying, with Novo Nordisk's recent FDA approval of Wegovy posing a potential challenge.
In Q4 2025, revenue increased by 420% YoY to $26,000, but the company reported a net loss of -$27.36M, albeit an 18.02% improvement YoY. EPS dropped by -21.21% YoY to -0.26, indicating ongoing financial struggles.
Analysts are optimistic with multiple Buy ratings and price targets ranging from $7 to $25. Key drivers include the potential of pemvidutide in treating liver diseases and alcohol use disorder, as well as a strong cash runway of $340M. However, one analyst views the stock as high risk/high reward, emphasizing the need for successful Phase III data.
